trial

Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study

NCTId NCT07309159
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Not Yet Recruiting
Enrollment 120 (estimated)
Sponsored by Centre Hospitalier Charles Perrens, Bordeaux
Primary completion 2027-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Not Yet Recruiting
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2026-06-01
Primary completion
2027-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ecological Momentary Assessment (EMA) and Reality Monitoring tasks

Sponsors

Centre Hospitalier Charles Perrens, BordeauxLead Sponsor

Investigators

1
David MISDRAHI, MDStudy Director

Sites

0 total

Linked catalysts

1
Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in P — primary completion2027-12-31

Facts & assertions

4 sourced
Enrollment
120
Phase
PHASE1,PHASE2
Primary Completion Date
2027-12-31
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
Ecological Momentary Assessment (EMA) and Reality Monitoring tasks
drug
lead_sponsor
Centre Hospitalier Charles Perrens, Bordeaux
company
indication
Schizophrenia
indication
Schizophrenia
indication
Marijuana Abuse
indication
investigator
David MISDRAHI, MD
person